Buscar
Mostrando ítems 1-10 de 170
Primary sclerosing cholangitis associated with severe ulcerative colitis in a young man
(2013)
Primary sclerosing cholangitis, a chronic progressive cholestatic liver disease, is the most serious hepatobiliary complication of ulcerative colitis (UC). The authors present the case of a severe and intractable form of ...
Feline cholangitis/ chonlangiohepatitis complex secondary to Platynosomum fastosum infection in a cat.
(2008-09-01)
Platynosomiasis has been associated with cholangitis/cholangiohepatitis complex in domestic cats. Despite being typically asymptomatic, some individuals may develop severe disease resulting in hepatic cirrhosis. Definitive ...
Feline cholangitis/ chonlangiohepatitis complex secondary to Platynosomum fastosum infection in a cat.
(2008-09-01)
Platynosomiasis has been associated with cholangitis/cholangiohepatitis complex in domestic cats. Despite being typically asymptomatic, some individuals may develop severe disease resulting in hepatic cirrhosis. Definitive ...
Primary sclerosing cholangitis and inflammatory bowel disease: Intestine---liver interrelation
(Elsevier, 2019)
The association between inflammatory bowel disease (IBD) and primary sclerosing cholangitis should be considered a distinct clinical entity. This association involves genetic abnormalities, epidemiological factors (more ...
Colangitis aguda debida a coledocolitiasis:¿Cirugía tradicional o drenaje biliar endoscópico?
(Sociedad Médica de Santiago, 2001)
Sin título
(2016)
Prevalencia y factores asociados a la colangitis aguda en el Hospital José Carrasco Arteaga. Cuenca 2019
(Universidad de Cuenca, 2021-05-14)
Introduction: Acute cholangitis remains a fatal disease in the absence of timely treatment and its diagnosis remains a challenge. Therefore, it is necessary to reveal the prevalence and the factors associated to the ...
High prevalence of BRAFV600E in patients with cholestasis, sclerosing cholangitis or liver fibrosis secondary to Langerhans cell histiocytosis
(Wiley-liss, div John Wiley & Sons Inc., 2021-07)
Targeted therapies with MAPK inhibitors have proven to modulate the clinical manifestations of patients with Langerhans cell histiocytosis (LCH). We explored the presence of BRAFV600E mutation in our cohort of patients ...